Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158501 | 0.82 | CNR1 (0.49) | PGRMAPTKMT2AALDH1A1LMNA | |
| SCHEMBL2157528 | 0.82 | PFKFB3 (0.52) | PGRMAPTKMT2AACLYPTGES2 | |
| SCHEMBL2157961 | 0.82 | GLO1 (0.46) | PGRMAPTKMT2AACLYALDH1A1 | |
| SCHEMBL2158526 | 0.81 | PGR (0.50) | PGRMAPTKMT2AALDH1A1LMNA | |
| SCHEMBL7579053 | 0.80 | PGR (0.75) | PGRMAPTPTPN2PTPN1PTPN5 | |
| SCHEMBL2158700 | 0.78 | ITGA1 (0.56) | PGRMAPTKMT2AACLYLMNA | |
| SCHEMBL6625839 | 0.78 | CA2 (0.63) | PGRMAPTKMT2AALDH1A1LMNA | |
| SCHEMBL2157586 | 0.78 | UQCRB (0.55) | MAPTPTPN5KMT2AALDH1A1LMNA | |
| SCHEMBL2158422 | 0.78 | ERAP1 (0.55) | PGRMAPTPTPN2PTPN1PTPN5 | |
| SCHEMBL2157783 | 0.77 | KMT2A (0.63) | PGRPTPN2PTPN1PTPN5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | PGR 4002/4885MAPT 1458/4885PTPN2 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.